The present invention provides assays for detecting and measuring the presence or level of anti-TNFalpha drug therapeutics and autoantibodies in a sample. The present invention is useful for optimizing therapy and monitoring patients receiving anti-TNFalpha drug therapeutics to detect the presence or level of autoantibodies (e.g., HACA and/or HAHA) against the drug.